购物车
- 全部删除
- 您的购物车当前为空
PD180970 是一种 Bcr-Abl 抑制剂,对于 p210Bcr-Abl、Src 和 Kit 的自磷酸化,IC50 分别为 5 nM、0.8 nM 和 50 nM。 PD180970 可用于慢性粒细胞白血病的研究。
为众多的药物研发团队赋能,
让新药发现更简单!
PD180970 是一种 Bcr-Abl 抑制剂,对于 p210Bcr-Abl、Src 和 Kit 的自磷酸化,IC50 分别为 5 nM、0.8 nM 和 50 nM。 PD180970 可用于慢性粒细胞白血病的研究。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 217 | 现货 | |
5 mg | ¥ 547 | 现货 | |
10 mg | ¥ 894 | 现货 | |
25 mg | ¥ 1,510 | 现货 | |
50 mg | ¥ 2,230 | 现货 | |
100 mg | ¥ 3,170 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 589 | 现货 |
产品描述 | PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit. PD180970 can be used in studies about chronic myelogenous leukemia. |
靶点活性 | c-Kit:50 nM, Src:0.8 nM, BCR-ABL:5 nM (Ip210Bcr-Ablkinase) |
体外活性 | In K562 cells, PD180970 (0.5 μM) induces apoptosis and causes cell death. The IC50 values are 170, 80, and 80 nM for the tyrosine phosphorylation of p210Bcr-Abl, Gab2, and CrkL. PD180970 significantly inhibits the purified recombinant Abl tyrosine kinase activity with an IC50 of 2.2 nM[1]. In the human K562 CML cells, PD180970 inhibits the activity of Stat5 DNA-binding with an IC50 of 5 nM[2]. |
体内活性 | In Male C57BL/6J mice injected with MPTP, intraperitonial injection of PD180970 (5 mg/kg) decreased number of activated microglia on activation by MPTP and reduces the Iba1 expression intensity in activated microglia[1]. |
别名 | PD 180970 |
分子量 | 429.27 |
分子式 | C21H15Cl2FN4O |
CAS No. | 287204-45-9 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 90.0 mg/mL (209.7 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.